---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-064022"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2024-05-23T23:59:59+00:00"
generated_at: "2026-06-01T09:20:35.782228+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Candel reports Phase 2 CAN-2409 data: 20.6-month median OS in NSCLC patients with ICI resistance

## Summary
- Median overall survival of 20.6 months in NSCLC patients with progressive disease despite ICI, vs 11.6 months historical SoC docetaxel.
- mOS of 22.0 months across all 46 patients with inadequate ICI response.
- 71.4% of evaluable metastatic patients had beneficial effect on both injected and uninjected tumors (abscopal response).
- Increased circulating CD8+ and CD4+ memory T cells after second injection correlated with prolonged survival.
- Favorable safety: no grade 4+ TRAEs; three grade 3 events (1 pyrexia, 2 pneumonitis).

## SEC filing metadata
- accession: 0000950170-24-064022
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2024-05-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017024064022/0000950170-24-064022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017024064022/cadl-20240523.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-064022
- JSON: https://secwatch.observer/filing/0000950170-24-064022.json
- Plain text: https://secwatch.observer/filing/0000950170-24-064022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.